RUDN Journal of MedicineRUDN Journal of MedicineВестник Российского университета дружбы народов. Серия: Медицина2313-02452313-0261Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)1663910.22363/2313-0245-2017-21-2-194-204ArticlesСтатьиResearch ArticleTHE BASICS OF CHEMOEMBOLIZATIONОСНОВЫ ХИМИОЭМБОЛИЗАЦИИ (обзор литературы)GitelsonD GГительзонД Г

interventional radiologist of the National Research Center for Hematology

врач рентгенэндоваскулярных диагностики и лечения научно-клинического отделения гематологической хирургии ФГБУ «Гематологический научный центр Министерства здравоохранения Российской Федерации»

gitelson@rambler.ruRogovD AРоговД Аkonovalov_oe@rudn.universityVasilievA EВасильевА Эkonovalov_oe@rudn.universityGitelsonE AГительзонЕ Аkonovalov_oe@rudn.universityNational Research Center for Hematology, Moscow, 125167, RussiaФГБУ «Гематологический научный центр Министерства здравоохранения Российской Федерации», Москва, РоссияRUDN University, Moscow, 117198, RussiaРоссийский университет дружбы народов, Москва, Россия15122017212VOL 21, NO2 (2017)ТОМ 21, №2 (2017)19420409092017Copyright ©; 2017, Gitelson D.G., Rogov D.A., Vasiliev A.E., Gitelson E.A.Copyright ©; 2017, Гительзон Д.Г., Рогов Д.А., Васильев А.Э., Гительзон Е.А.2017Gitelson D.G., Rogov D.A., Vasiliev A.E., Gitelson E.A.Гительзон Д.Г., Рогов Д.А., Васильев А.Э., Гительзон Е.А.http://creativecommons.org/licenses/by/4.0https://journals.rudn.ru/medicine/article/view/16639

Chemoembolization has advantages over systemic chemotherapy as increase in drug concentration, time of exposition and decrease in systemic adverse effects.

В статье рассматривается повышение концентрации химиопрепарата, увеличение времени экспозиции в опухолевой ткани и уменьшение системных токсических реакций, которое можно получить при использовании химиоэмболизации.

chemoembolizationlocal chemotherapytumorхимиоэмболизациялокальная химиотерапияопухольDolgushin B. I., Patutko Yu. I., Virshke E. R., Trofimov I. A., Cherkasov V. A., Kukushkin A. V., Kosirev V. Yu. & Sergeeva O. N. Arterialnaya himioembolizaciya mikrosferami, perenosyashimi dok-sorubicin, v lechenii bolnih gepatocellularnim rakom. Predvaritelnie resultati. Anali hirurgicheskoi gepatologii. 2009. Т. 14, N 2. С. 53—58.Долгушин Б.И., Патютко Ю.И., Виршке Э.Р., Трофимов И.А., Черкасов В.А., Кукушкин А.В., Косырев В.Ю., Сергеева О.Н. Артериальная химиоэмболизация микросферами, переносящими доксорубицин (DC Bead™), в лечении больных гепатоцеллюлярным раком. Предварительные результаты // Анналы хирургической гепатологии. 2009. Т. 14. № 2. С. 53-58.Komov D. V., Roshin E. M., Kuchinskii G. A., Dolgushin B. I. & Virshke E. R. Itogi pervoi fazi klinicheskih issledovanii kompleksa doxorubicin-estron u bolnih so zlokachestvennimi novoobra-zovaniyami pecheni pri himiembolizacii c lipiodolom. Vestnik ONC AMN Rossii. 1997. N 4. С. 34—37.Комов Д.В., Рощин Е.М., Кучинский Г.А., Долгушин Б.И., Виршке Э.Р. и др. Итоги первой фазы клинических исследований комплекса доксорубицин-эстрон у больных со злокачественными новообразованиями печени при химиоэмболизации с липиодолом // Вестник ОНЦ АМН России. 1997. № 4. С. 34-37.Abdel-Rahman O. M. & Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepa-tocellular carcinoma. Cochrane Database Syst Rev. 2016. N 2. CD 011313.Abdel-Rahman O.M., Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma // Cochrane Database Syst Rev. 2016. N 2. CD 011313.Arciero C. A. & Sigurdson E.R. Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw. 2006. V. 4. N 8. P. 768—774.Arciero C.A., Sigurdson E.R. Liver-directed therapies for hepatocellular carcinoma // J Natl Compr Canc Netw. 2006. V. 4. N 8. P. 768-774.Arciero C. A. & Sigurdson E. R. Liver-directed therapies for patients with primary liver cancer and hepatic metastases. Curr Treat Options Oncol. 2006. V. 7. N 5. P. 399—409.Arciero C.A., Sigurdson E.R. Liver-directed therapies for patients with primary liver cancer and hepatic metastases // Curr Treat Options Oncol. 2006. V. 7. N 5. P. 399-409.Brown D.B. & Gould J. E. Practice building in interventional oncology. Tech Vasc Interv Radiol. 2006. V. 9. N 3. P. 90—95.Brown D.B., Gould J.E. Practice building in interventional oncology // Tech Vasc Interv Radiol. 2006. V. 9. N 3. P. 90-95.Gamma C., Schepis F., Orlando A. et al. Transarterial chemoembolization for unresectable hepato-cellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002. V. 224. P. 47—54.Gamma C., Schepis F., Orlando A. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials // Radiology. 2002. V. 224. P. 47-54.Granov A. M., Tarazov P. G., Granov D. A., Polikarpov A. A. & Oleshchuk N. V. Successful treat-ment of patient with recurrent hepatocellular carcinoma. Vestn Khir Im I I Grek. 2015. V. 1. N 2. P. 98—100.Granov A.M., Tarazov P.G., Granov D.A., Polikarpov A.A., Oleshchuk N.V. Successful treatment of patient with recurrent hepatocellular carcinoma // Vestn Khir Im I I Grek. 2015. V. 1. N 2. P. 98-100.Guan Y. S., He Q. & Wang M. Q. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012. 480650.Guan Y.S., He Q., Wang M.Q. Transcatheter arterial chemoembolization: history for more than 30 years // ISRN Gastroenterol. 2012. 480650.Huang K., Zhou Q., Wang R., Cheng D. & Ma Y. Doxorubicin-eluting beads versus conventional tran-sarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014. V. 29. N 5. P. 920—925.Huang K., Zhou Q., Wang R., Cheng D., Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma // J Gastroenterol Hepatol. 2014. V. 29. N 5. P. 920-925.Kurup A. N. & Callstrom M. R. Ablation of musculoskeletal metastases: pain palliation, fracture risk reduction, and oligometastatic disease. Tech Vasc Interv Radiol. 2013. V. 16. N 4. P. 253—261.Kurup A.N., Callstrom M.R. Ablation of musculoskeletal metastases: pain palliation, fracture risk reduction, and oligometastatic disease // Tech Vasc Interv Radiol. 2013. V. 16. N 4. P. 253-261.Llovet J. M. & Bruix J. Systematic review of randomized trials for unresectable hepatocellular carci-noma: Chemoembolization improves survival. Hepatology. 2003. V. 37. P. 429—442.Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival // Hepatology. 2003. V. 37. P. 429-442.Llovet J. M. & Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial emboliza-tion. Radiology. 2004. V. 2. N 1. P. 300—301.Llovet J.M., Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization // Radiology. 2004. V. 2. N 1. P. 300-301.Llovet J. M., Real M. I., Montaña X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Solà R., Rodés J. & Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoemboli-sation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a random-ised controlled trial. Lancet. 2002. V. 18. P. 1734—1739.Llovet J.M., Real M.I., Montaña X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Solà R., Rodés J., Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial // Lancet. 2002. V. 18. P 1734-1739.Lo C. M., Ngan H., Tso W. K. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002. V. 35. P. 1164—1171.Lo C.M., Ngan H., Tso W.K. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma // Hepatology. 2002. V. 35. P. 1164- 1171.Malagari K., Chatzimichael K., Alexopoulou E. et al. Transarterial chemoembolization. World J Gastroenterol. 2015.V. 2. № 9. P. 420—424.Malagari K., Chatzimichael K., Alexopoulou E. et al. Transarterial chemoembolization // World J Gastroenterol. 2015.V. 2. N 9. P. 420-424.Miraglia R., Pietrosi G., Maruzzelli L., Petridis I., Caruso S., Marrone G., Mamone G., Vizzini G., Luca A. & Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol. 2007. V. 7. N 13. P. 2952—2955.Miraglia R., Pietrosi G., Maruzzelli L., Petridis I., Caruso S., Marrone G., Mamone G., Vizzini G., Luca A., Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma // World J Gastroenterol. 2007. V. 7. N 13. P. 2952-2955.Park Y. N. & Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol. 2006. V. 45. N 5. P. 734—743.Park Y.N., Roncalli M. Large liver cell dysplasia: a controversial entity // J Hepatol. 2006. V. 45. N 5. P. 734-743.Pereira P. L. & Masala S. Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: guidelines for thermal ablation of primary and secondary lung tu-mors. Cardiovasc Intervent Radiol. 2012. V. 35. N 2. P. 247—254.Pereira P.L., Masala S. Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors // Cardiovasc Intervent Radiol. 2012. V. 35. N 2. P. 247-254.Rammohan A., Sathyanesan J., Ramaswami S., Lakshmanan A., Senthil-Kumar P., Srini¬vasan U. P., Ramasamy R. & Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012. V. 28. № 4. P. 405—412.Rammohan A., Sathyanesan J., Ramaswami S., Lakshmanan A., Senthil-Kumar P., Srinivasan U.P., Ramasamy R., Ravichandran P. Embolization of liver tumors: Past, present and future // World J Radiol. 2012. V. 28. N 4. P. 405-412.The Royal College of Radiologists UK. Interventional Oncology: Guidance for Service delivery 2013—2016.The Royal College of Radiologists UK. Interventional Oncology: Guidance for Service delivery 2013-2016.Tian X., Dai Y., Wang D. Q., Zhang L., Sui C. G., Meng F. D., Jiang S. Y., Liu Y. P. & Jiang Y. H. Tran-sarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. Drug Des Devel Ther. 2015. V 10. N 9. P. 4431—4440.Tian X., Dai Y., Wang D.Q., Zhang L., Sui C.G., Meng F.D., Jiang S.Y., Liu Y.P., Jiang Y.H. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis // Drug Des Devel Ther. 2015. V 10. N 9. P. 4431-4440.Varela M., Real M. I., Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Hepatology. 2007. V. 46. N 3. P. 474—481.Varela M., Real M.I., Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics // Hepatology. 2007. V. 46. N 3. P. 474-481.Bruix J., Sala M. & Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004. V. 5. N 1. P. 179—188.Bruix J., Sala M., Llovet J.M. Chemoembolization for hepatocellular carcinoma // Gastroenterology. 2004. V. 5. N 1. P. 179-188.Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M. & Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with in-traarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989. V. 97. N 4. P. 965—971.Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M., Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil // Gastroenterology. 1989. V. 97. N 4. P. 965-971.Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P. & Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unre¬sectable hepatocel-lular carcinoma. J Hepatol. 1990. V. 11. N 2. P. 181—184.Pelletier G., Roche A., Ink O., Anciaux M.L., Derhy S., Rougier P., Lenoir C., Attali P., Etienne J.P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma // J Hepatol. 1990. V. 11. N 2. P. 181-184.Kawai S., Okamura J., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma — a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 1—6.Kawai S., Okamura J., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y., Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan // Cancer Chemother Pharmacol. 1992. V. 31. P. 1-6.Okamura J., Kawai S., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y. & Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carci-noma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second coopera-tive study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992. V. 31. P. 20—24.Okamura J., Kawai S., Ogawa M., Ohashi Y., Tani M., Inoue J., Kawarada Y., Kusano M., Kubo Y., Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan // Cancer Chemother Pharmacol. 1992. V. 31. P. 20-24.Watanabe S., Nishioka M., Ohta Y., Ogawa N., Ito S. & Yamamoto Y. Prospective and random-ized controlled study of chemoembolization therapy in patients with advanced hepatocellular car-cinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol. 1994. V. 33. P. 93—96.Watanabe S., Nishioka M., Ohta Y., Ogawa N., Ito S., Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area // Cancer Chemother Pharmacol. 1994. V. 33. P. 93-96.